IC
ALXN

IEQ Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

IEQ Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,943
Closed -$357K – 711
2021
Q2 		$357K Buy
1,943
+553
+40% +$94.9K 0.01% 423
2021
Q1 		$213K Buy
+1,390
New +$215K 0.01% 450

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

IEQ Capital's ALXN Position: Q3 2021 in Review

IEQ Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,943 shares — an estimated $357K sold.

IEQ Capital first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $357K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • IEQ Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • IEQ Capital sold 1,943 Alexion Pharmaceuticals shares in Q3 2021, an estimated $357K.
  • IEQ Capital first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • IEQ Capital's Alexion Pharmaceuticals position peaked at $357K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on IEQ Capital's 13F filing for Q3 2021, filed 9 Nov 2021.